US firm (Myriad) corners exclusive license for RAD51C (breast/ovarian)cancer gene : The Lancet Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, February 16, 2012

US firm (Myriad) corners exclusive license for RAD51C (breast/ovarian)cancer gene : The Lancet Oncology



 abstract

"Already facing a legal challenge to its BRCA1 and BRCA2 patents, Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive licence for another breast and ovarian cancer-associated gene, RAD51C , under agreement with the German Consortium for Hereditary Breast and Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.
“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University ..."

To read this article in full you will need to make a payment

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.